Genentech, a member of the Roche (RHHBY) Group, announced the company’s first Direct-to-Patient program. “This program, which supports President Trump’s goal to make medicines more affordable for American patients, applies to Xofluza, a single-dose oral antiviral medication used to treat the flu in patients ages five and up as well as those who have been exposed to the flu. This initiative will help reduce costs for people who don’t have insurance, have limited coverage, or whose health plans don’t cover Xofluza. Genentech is collaborating with three pharmacies to offer the medication with a prescription: Alto Pharmacy Powered by Fuze Health, Amazon Pharmacy, and Mark Cuban Cost Plus Drug Company, PBC,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche says FDA clears Elecsys pTau181 test
- Roche to present 30 abstracts at ESMO, evERA study met co-primary endpoints
- Natera to present 14 studies to be presented at ESMO Congress
- Trump Weekly: Generics to be excluded from pharma tariff plan
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx